Liebenberg W et al., 1998-05: A South African preformulation study showing that raw material lots varied (three polymorph C, one form A or an A/B mixture) while all four finished tablets on the local market contained polymorph C. It documents both the product-level consistency and the raw-material risk.
Literature prescribes the use of polymorph C pharmaceutically, but generic manufacturers should be aware that forms other than C are still available on the market. The four mebendazole tablets currently available in South Africa were also tested and it was found that all of them contained polymorph C.
abstract
Liebenberg W et al., 1998-05: A South African preformulation study showing that raw material lots varied (three polymorph C, one form A or an A/B mixture) while all four finished tablets on the local market contained polymorph C. It documents both the product-level consistency and the raw-material risk. Study type: pharmaceutical analytical study (X-ray powder diffractometry, IR, dissolution). N: four raw material samples and four commercial tablet products. Country: South Africa (Potchefstroom University). No patients, no dosing. Funder/conflicts: not stated in the abstract. Manufacturer names of the four products not given in the abstract. Comparator: reference polymorphs A, B, C. Documents the practical point that 'which form is in which product' varies by supplier and lot, not by brand alone. Also filed as MBD-27 (claims C5, C8). Study type: lab.
